PMID- 30584299
OWN - NLM
STAT- MEDLINE
DCOM- 20190204
LR  - 20231004
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 13
DP  - 2018
TI  - Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics 
      in vitro.
PG  - 8269-8279
LID - 10.2147/IJN.S180503 [doi]
AB  - In recent times, co-delivery of therapeutics has emerged as a promising strategy 
      for treating dreadful diseases such as cancer. MATERIALS AND METHODS: In this 
      study, we developed a novel nanocarrier based on bacterial magnetosomes (BMs) 
      that co-loaded with siRNA and doxorubicin (DOX) using polyethyleneimine (PEI) as 
      a cross-linker (BMs/DP/siRNA). The delivery efficiency of siRNA as well as the 
      pH-responsive release of DOX, and synergistic efficacy of these therapeutics in 
      vitro were systematically investigated. RESULTS: The structure of DOX-PEI (DP) 
      conjugates that synthesized via hydrazone bond formation was confirmed by 1H 
      nuclear magnetic resonance (NMR). The in vitro release experiments showed that 
      the DP conjugate (DOX-loading efficiency - 5.77%+/-0.08%) exhibited the long-term 
      release behavior. Furthermore, the optimal BMs/DP/siRNA particle size of 107.2 nm 
      and the zeta potential value of 31.1+/-1.0 mV facilitated enhanced cellular 
      internalization efficiency. Moreover, the agarose gel electrophoresis showed that 
      the co-delivery system could protect siRNA from degradation in serum and RNase A. 
      In addition, the cytotoxicity assay showed that BMs/DP/siRNA could achieve an 
      excellent synergistic effect compared to that of siRNA delivery alone. The 
      acridine orange (AO)/ethidium bromide (EB) double staining assay also showed that 
      BMs/DP/siRNA complex could induce cells in a stage of late apoptosis and 
      nanocomplex located in the proximity of the nucleus. CONCLUSION: The combination 
      of gene and chemotherapeutic drug using BMs is highly efficient, and the 
      BMs/DP/siRNA would be a promising therapeutic strategy for the future 
      therapeutics.
FAU - Long, Rui-Min
AU  - Long RM
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China, 
      ygliu@hqu.edu.cn.
AD  - Fujian Provincial Key Laboratory of Biochemical Technology, Huaqiao University, 
      Xiamen 361021, China, ygliu@hqu.edu.cn.
FAU - Dai, Qing-Lei
AU  - Dai QL
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China, 
      ygliu@hqu.edu.cn.
FAU - Zhou, Xia
AU  - Zhou X
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China, 
      ygliu@hqu.edu.cn.
FAU - Cai, Duan-Hua
AU  - Cai DH
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China, 
      ygliu@hqu.edu.cn.
FAU - Hong, Ya-Zhen
AU  - Hong YZ
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China, 
      ygliu@hqu.edu.cn.
AD  - Fujian Provincial Key Laboratory of Biochemical Technology, Huaqiao University, 
      Xiamen 361021, China, ygliu@hqu.edu.cn.
AD  - Institute of Pharmaceutical Engineering, Huaqiao University, Xiamen 361021, 
      China, ygliu@hqu.edu.cn.
FAU - Wang, Shi-Bin
AU  - Wang SB
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China, 
      ygliu@hqu.edu.cn.
AD  - Fujian Provincial Key Laboratory of Biochemical Technology, Huaqiao University, 
      Xiamen 361021, China, ygliu@hqu.edu.cn.
AD  - Institute of Pharmaceutical Engineering, Huaqiao University, Xiamen 361021, 
      China, ygliu@hqu.edu.cn.
AD  - Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen 
      361021, China.
FAU - Liu, Yuan-Gang
AU  - Liu YG
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China, 
      ygliu@hqu.edu.cn.
AD  - Fujian Provincial Key Laboratory of Biochemical Technology, Huaqiao University, 
      Xiamen 361021, China, ygliu@hqu.edu.cn.
AD  - Institute of Pharmaceutical Engineering, Huaqiao University, Xiamen 361021, 
      China, ygliu@hqu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20181204
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Drug Carriers)
RN  - 0 (RNA, Small Interfering)
RN  - 80168379AG (Doxorubicin)
RN  - 9002-98-6 (Polyethyleneimine)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Cell Survival/drug effects
MH  - Doxorubicin/chemistry/pharmacology
MH  - Drug Carriers/*chemistry
MH  - HeLa Cells
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Magnetosomes/*chemistry
MH  - Magnetospirillum/*chemistry
MH  - Nanoparticles/*chemistry
MH  - Neoplasms/*drug therapy
MH  - Particle Size
MH  - Polyethyleneimine/chemical synthesis/chemistry
MH  - Proton Magnetic Resonance Spectroscopy
MH  - RNA, Small Interfering/genetics
PMC - PMC6289231
OTO - NOTNLM
OT  - bacterial magnetosomes
OT  - co-delivery
OT  - gene therapy
OT  - pH-responsive release
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/12/26 06:00
MHDA- 2019/02/05 06:00
PMCR- 2018/12/04
CRDT- 2018/12/26 06:00
PHST- 2018/12/26 06:00 [entrez]
PHST- 2018/12/26 06:00 [pubmed]
PHST- 2019/02/05 06:00 [medline]
PHST- 2018/12/04 00:00 [pmc-release]
AID - ijn-13-8269 [pii]
AID - 10.2147/IJN.S180503 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2018 Dec 4;13:8269-8279. doi: 10.2147/IJN.S180503. 
      eCollection 2018.